Immunisation of large mammals with low doses of RNA
AssigneeGlaxosmithkline Biologicals SA
InventorAndrew Geall
Life of this patent
Estimating the term…
Abstract
RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
Claims20
A method of eliciting an antibody response and/or a cell-mediated immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of a self-replicating RNA encoding an immunogen, wherein the large mammal is a human, horse, cattle or pig and the RNA is formulated with a non-viral delivery system that comprises liposomes comprising a cationic lipid comprising a tertiary amine, wherein the self-replicating RNA:
- i) cannot perpetuate itself in infectious form and ii) includes no modified nucleotides other than a 5′ cap.
A method of eliciting an antibody response and/or a cell-mediated immune response in a large mammal, comprising administering to the mammal between 0.1 μg and 1.5 μg RNA per kg of the mammal's body weight, wherein the large mammal is a human, horse, cattle or pig and said RNA is a self-replicating RNA that encodes an immunogen, and wherein said RNA is formulated with a non-viral delivery system that comprises liposomes comprising a cationic lipid comprising a tertiary amine, wherein the self-replicating RNA:
- i) cannot perpetuate itself in infectious form and ii) includes no modified nucleotides other than a 5′ cap.
Dependencies are inferred from the claim text.